Filtering





Contrast enhanced ultrasound and elastography for IBD monitoring?8th ECCO Ultrasound Workshop - Advanced in collaboration with ESGAR
Year: 2021
Authors: Krisztina B. Gecse
Summary content

1. To understand the basics of CEUS and elastography
2. To review the currently available literature on CEUS and elastography in IBD
3. To identify future directions of research

Current knowledge: What is the problem with FMT therapy?ECCO'21 Virtual
Year: 2021
Authors: Marie Joossens
Summary content

Current knowledge: What is the problem with FMT therapy?
Complexity of multifactorial diseases complicate simple treatment

Datasets and standards for IBD pathology6th H-ECCO IBD Masterclass
Year: 2021
Authors: Roger M. Feakins
Summary content

1. To consider the factors that affect standards in IBD pathology
2. To explore the availability and content of IBD pathology guidelines and datasets

The lecture outlines some of the factors that influence standards and considers approaches to the improvement of IBD pathology reporting quailty.

Deep healingECCO'21 Virtual
Year: 2021
Authors: Marc Ferrante
Diagnosis, anatomy and physiology in IBD12th N-ECCO School
Year: 2021
Authors: Marc Ferrante
Summary content

1. To understand normal physiology of the gastrointestinal tract
2. To review the etiopathogenesis of Inflammatory Bowel Diseases
3. To emphasize the different modalities to diagnose Inflammatory Bowel Diseases
4. To have an overview of the most commonly used clinical and endoscopic activity scores for Inflammatory Bowel Diseases

Although extra-intestinal manifestations are common, inflammatory bowel diseases (IBD) typically affect the intestine. Where ulcerative colitis (UC) is limited to the colon, Crohn’s disease (CD) may involve all parts of the gastrointestinal tract (mouth, oesophagus, stomach, small intestine, colon and rectum). Consequently, the function of all these segments may be compromised.

Although the exact etiopathogenesis of IBD has not been unravelled, the prevailing model states that IBD is driven by environmental factors in genetically susceptible individuals, resulting in a dysregulated immune response towards the intestinal microbiome.

Besides a good clinical history and physical examination, several diagnostic tools will help the physician to diagnose IBD. These tools include lab test (both blood and faeces), radiological examination (ultrasound, CT and MR scan), and endoscopy with biopsies for histological examination.

Clinical disease activity of CD and UC, are most commonly assessed using the Harvey-Bradshaw index and the Mayo score, respectively. However, patient reported outcomes become more frequently implemented. Also endoscopic disease activity indices have been introduced in daily clinical care. For CD, the Crohn’s disease endoscopic index of severity (CDEIS), the simple endoscopic score for Crohn’s disease (SES-CD), and the Rutgeerts score are used. For UC, the Mayo score and the ulcerative colitis endoscopic index of severity (UCEIS) are employed. C-reactive protein (CRP) and faecal calprotectin could be regarded as surrogate markers for endoscopic disease activity, but their accuracy is not optimal.

Digital pathology and artificial intelligence in IBD pathology6th H-ECCO IBD Masterclass
Year: 2021
Authors: Francesca Rosini
Summary content

Artificial Intelligence and Digital Pathology are rapidly growing disciplines that have the potential to revolutionise the field of inflammatory bowel disease. ML and DL approaches offer the ability to synthesise and incorporate large amounts of data to improve diagnostic accuracy, uncover new disease associations, identify at risk individuals, and guide therapeutic decision making. While challenges to the routine use of DP and AI in IBD remain, continued exploration of possible applications are expected to accelerate the drive toward precision medicine.
-To understand basic principles of Digital Pathology and Artificial Intelligence.
-To review pros and cons of DP and AI.
-To have an overview of DP and AI in IBD pathology.

Discussion about scoring systems6th H-ECCO IBD Masterclass
Year: 2021
Authors: Ann Driessen, Gert De Hertogh, Fernando Magro
Discussion: Drug efficacy4th School for Clinical Trialists
Year: 2021
Authors: Uri Kopylov, Stefanos Bonovas, Peter Bossuyt, Parambir Dulai, Geert D'Haens, Alissa Jane Walsh, Gemma Wakefield
Discussion: Drug safety4th School for Clinical Trialists
Year: 2021
Authors: Peter Bossuyt, Julien Kirchgesner, Katrien Asnong, Laurent Beaugerie, Adrien Inoubli
Discussion: How to fill in the gaps of knowledge in orphan IBD populations5th Advanced ECCO: EduCational COurse for Industry
Year: 2021
Authors: Krisztina B. Gecse, Slobodan Milicevic, Laurent Beaugerie, Silvio Danese, Geert D'Haens, Azmina Rose
Discussion: Pelvic fistula is a nightmare!10th S-ECCO IBD Masterclass
Year: 2021
Authors: Phillip Fleshner, Willem Bemelman
Discussion: Precision medicine in IBD therapy5th Advanced ECCO: EduCational COurse for Industry
Year: 2021
Authors: Gerhard Rogler, Edouard Louis, Shaji Sebastian, Séverine Vermeire, KT Park
Discussion: Surgical technique session: The redo-session10th S-ECCO IBD Masterclass
Year: 2021
Authors: Janindra Warusavitarne, Oded Zmora
Discussion: What to do with these abdominal fistula?10th S-ECCO IBD Masterclass
Year: 2021
Authors: Pär Myrelid, Gianluca Matteo Sampietro
Disease burdenECCO'21 Virtual
Year: 2021
Authors: Catherine Le Berre
Summary content

1. To understand the similarity between both types of IBD regarding structural and functional damage
2. To review the risk of intestinal cancer in both types of IBD
3. To review the prevalence of extra-intestinal manifestations (EIMs) in both Crohn's disease and ulcerative colitis
4. To emphasise the impact that both UC and CD can have on patient's life (quality of life, disability, fatigue, anxiety/depression, work productivity)
5. To have an overview of the economic burden of IBD in 2021

Do guidelines prevent patient-centred care (Tandem Talk)2nd Guideline Methodology and GRADE Workshop
Year: 2021
Authors: Susanna Jäghult, Hannah Gordon
Summary content

1. To understand the background and benefits of Patient centered care

2. To review the evidence of Patient centered care

3. To learn about both benefits and disadvantages with patient involvement when developing guidelines

Do we still need RCTs? (Tandem Talk)4th School for Clinical Trialists
Year: 2021
Authors: Geert D'Haens, Uri Kopylov
Drug efficacy: What are the expectations? (Tandem Talk)4th School for Clinical Trialists
Year: 2021
Authors: Gemma Wakefield, Alissa Jane Walsh
Drug safety in the elderly patients with IBDECCO'21 Virtual
Year: 2021
Authors: Triana Lobatón Ortega
Dyeless or still dye chromoendoscopy: How do I use curriculum to achieve competency and be an excellent IBD endoscopist?3rd ECCO Basic Imaging Workshop in collaboration with ESGAR: Endoscopy
Year: 2021
Authors: Raf Bisschops